Right now, GlaxoSmithKline’s meningitis B vaccine, Bexsero, doesn’t have the key “universal use” endorsement the company wants from the CDC. So it’s spreading…

Mylan has been pummeled by media, consumers, patients, pundits, politicians and even celebrities over charges of jacking up the price for its EpiPen auto…

Pharma ads may be ubiquitous during prime-time TV, but during the Olympic Games in Rio? Not so much. With $1.18 billion spent overall, pharma only accounted…

Big Pharma's emerging markets sales growth plunged to a new low last quarter. But within the group's overall average, some companies--such as…

Dublin-based Mallinckrodt company has decided it needs a U.S. campus to consolidate workers picked up in an M&A spree, as well as some more manufacturing,…

Mylan is facing the prospect of investigations--as well as public criticism--following years of price increases on its big-selling EpiPen.

When one M&A door closes, many windows open. After Pfizer wrapped up a $14B Medivation buy Monday, investors bid up BioMarin, Incyte and more as likely…

Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.